Passage Bio (PASG)

• Market cap: $23.8M
• 1 day: 0.68%
• 5 days: -1.46%
• 1 month: -13.7%
• 3 months: -25.63%
• 6 months: -1.46%
• Year to date: -36.44%
• 1 year: -21.95%
• 5 years: -98.03%
• 10 years: -98.33%
• Sector: Healthcare
• Industry: Biotechnology

About: Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Employees: 24